BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld Asia
Home
» Australia's Bionomics revives BNC-210 in PTSD following analysis of phase II failure
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Australia's Bionomics revives BNC-210 in PTSD following analysis of phase II failure
Feb. 20, 2019
By
Tamra Sami
No Comments
PERTH, Australia – Adelaide-based Bionomics Inc. is reviving lead compound BNC-210 after a deeper analysis of phase II data showed a positive effect in post-traumatic stress disorder (PTSD).
BioWorld Asia